IR@PKUHSC  > 北京大学第三临床医学院
学科主题临床医学
Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial
Huang, Liang1,2; Chen, Sheng1,2; Yang, Wentao2,3; Xu, Binghe4,5,6; Huang, Tao7; Yang, Hongjian8; Zheng, Hong9,10; Wang, Yongsheng11; Song, Erwei12; Zhang, Jin13; Cui, Shude14; Pang, Da15; Tang, Lili16; Lei, Yutao17; Geng, Cuizhi18; Shao, Zhiming1,2
关键词neoadjuvant chemotherapy trastuzumab pathological complete response clinical trial carboplatin anthracycline
刊名ONCOTARGET
2015-07-30
6期:21页:18683-18692
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Cell Biology
研究领域[WOS]Oncology ; Cell Biology
关键词[WOS]PATHOLOGICAL COMPLETE RESPONSE ; PIK3CA MUTATIONS ; ADJUVANT TRASTUZUMAB ; CARDIAC SAFETY ; CHEMOTHERAPY ; DOXORUBICIN ; RESISTANCE ; POLYMORPHISMS ; WOMEN ; ACTIVATION
英文摘要

This trial was designed to compare the efficacy and safety between epirubicin (E) and carboplatin (C) in combination with paclitaxel (P) and trastuzumab (H) in neoadjuvant setting. In 13 Chinese cancer centers, 100 patients with HER2-positive, locally advanced breast cancer were 1: 1 randomized to receive medication as follows: trastuzumab and paclitaxel weekly combined with carboplatin weekly for PCH group, or epirubicin every 3 weeks for PEH group. Patients were given 4 to 6 cycles of chemotherapy. The primary endpoint was pathologic complete response (pCR) rate, which was no significant difference in PCH and PEH regimen (39.1% vs. 48.8%; p=0.365). However, PEH regimen achieved higher pCR in luminal-B (HER2-poitive) subgroup (55.0% vs. 24.0%; p=0.033), but not in ERBB2+ subgroup (42.9% vs. 57.1%; p=0.355). PEH regimen showed a favorable efficacy in PIK3CA mutated subgroup (69.2% vs. 23.5%, p=0.012). No significant difference was observed in the subgroup analysis of TP53 mutation status, PTEN expression, FCGR2A SNP and FCGR3A SNP. Both regimens as neoadjuvant chemotherapy achieve similar efficacy and safety. PEH might improve pCR rate, especially in the luminal-B subtype and PIK3CA mutation subtype. PEH is feasible and less likely to increase the incidence of acute cardiac events compared to PCH.

语种英语
WOS记录号WOS:000359015900039
引用统计
被引频次:9[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64887
专题北京大学第三临床医学院
作者单位1.Fudan Univ, Inst Canc, Dept Breast Surg, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
2.Ctr Canc, Inst Canc, Dept Pathol, Shanghai, Peoples R China
3.Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200433, Peoples R China
4.Chinese Acad Med Sci, Inst Canc, Dept Med Oncol, Beijing 100730, Peoples R China
5.Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
6.Peking Union Med Coll, Beijing 100021, Peoples R China
7.Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Breast & Thyroid Surg, Wuhan 430074, Peoples R China
8.Zhejiang Canc Hosp, Dept Breast Tumor Surg, Hangzhou, Zhejiang, Peoples R China
9.Sichuan Univ, Ctr Canc, Dept Head & Neck & Mammary Oncol, Chengdu 610064, Peoples R China
10.Sichuan Univ, West China Hosp, Lab Mol Diag Canc, State Key Lab Biotherapy, Chengdu 610064, Peoples R China
11.Shandong Canc Hosp & Inst, Breast Canc Ctr, Jinan, Peoples R China
12.Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510275, Guangdong, Peoples R China
13.Tianjin Med Univ, Canc Inst & Hosp, Dept Breast Canc 3, Tianjin, Peoples R China
14.Henan Canc Hosp, Henan Breast Canc Ctr, Zhengzhou, Peoples R China
15.Harbin Med Univ, Affiliated Hosp 3, Dept Breast Surg, Harbin, Peoples R China
16.Cent S Univ, Xiangya Hosp, Dept Breast Surg, Changsha, Hunan, Peoples R China
17.Peking Univ, Hosp 3, Dept Breast Surg, Beijing 100871, Peoples R China
18.Hebei Med Univ, Hosp 4, Dept Breast Canc Ctr, Shijiazhuang, Peoples R China
推荐引用方式
GB/T 7714
Huang, Liang,Chen, Sheng,Yang, Wentao,et al. Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial[J]. ONCOTARGET,2015,6(21):18683-18692.
APA Huang, Liang.,Chen, Sheng.,Yang, Wentao.,Xu, Binghe.,Huang, Tao.,...&Shao, Zhiming.(2015).Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial.ONCOTARGET,6(21),18683-18692.
MLA Huang, Liang,et al."Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial".ONCOTARGET 6.21(2015):18683-18692.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Huang, Liang]的文章
[Chen, Sheng]的文章
[Yang, Wentao]的文章
百度学术
百度学术中相似的文章
[Huang, Liang]的文章
[Chen, Sheng]的文章
[Yang, Wentao]的文章
必应学术
必应学术中相似的文章
[Huang, Liang]的文章
[Chen, Sheng]的文章
[Yang, Wentao]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。